You are here:


AOP Orphan Contact

AOP Orphan worldwide

Wilhelminenstraße 91/IIf
1160 Vienna, Austria
office(at)aoporphan.com

Research & Development


High rates of durable hematological response and symptom control with good tolerability were reconfirmed with Ropeginterferon alfa-2b after 36 months of treatment. Disease Modification by Ropeginterferon alfa-2b was...

22.11.2018:

LANDI-SEP Trials 2018

Study protocol "Landiolol in patients with septic shock resident in an intensive care unit (LANDISEP): study protocol for a randomized controlled trial" Download the LANDI-SEP Trials 2018 here

On November 13th AOP Orphan was awarded with the MERCUR prize for Innovation in Life Science by the Chamber of Commerce in Vienna, Austria. We feel very proud to receive this recognition and want to thank all colleagues, partners...

Abstract Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden...

EMA started the centralized marketing authorization procedure for Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) on Feb 23rd 2017.
Ropeginterferon alfa-2b is a novel mono-pegylated interferon with an improved...

At 12 months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) PROUD-PV demonstrated a significantly better safety and tolerability profile of ropeginterferon...

INDIANAPOLIS, IN — CONFLUENCE PHARMACEUTICALS and AOP Orphan Pharmaceuticals AG (“AOP”), announced today they have signed a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of...

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in Central and Eastern Europe.

Non-inferiority of anagrelide compared to hydroxyurea in WHO-essential ET. (Prepublished online, Blood, Jan. 11, 2013)

AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b...

With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan. AOP Orphan is an Austrian...